TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care. The main questions it aims to answer are: 1. To evaluate the safety and tolerability of TT-10, TT-4 Diacid, and combination therapy (TT-10 + TT-4 Diacid). 2. To determine the maximum tolerated dose (MTD) or phase 2 recommended dose of TT-10, TT-4 Diacid, and combination therapy (TT-10 + TT-4 Diacid). 3. To evaluate safety of combination therapy (TT-10 + TT-4 Diacid).

Trial Details

NCT ID
NCT04969315
Phase
PHASE1 / PHASE2
Sponsor
Portage Biotech
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • TT-10
  • TT-4
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Male or female participants must be ≥18 years of age on the day of signing the ICF.
  • Participants or their legal representative must be able to provide written informed consent to participate in the study prior to the performance of…
  • Diagnosis of histologically or cytologically confirmed advanced selected solid tumors:
  • All Cohorts

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →